Enliven Therapeutics ELVN Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's operating lease liabilities (current)?
- Enliven Therapeutics (ELVN) reported operating lease liabilities (current) of $302K in Q1 2026.
- How has Enliven Therapeutics's operating lease liabilities (current) changed year-over-year?
- Enliven Therapeutics's operating lease liabilities (current) decreased by 17.3% year-over-year, from $365K to $302K.
- What is the long-term trend for Enliven Therapeutics's operating lease liabilities (current)?
- Over 2 years (2021 to 2025), Enliven Therapeutics's operating lease liabilities (current) has grown at a 27.4% compound annual growth rate (CAGR), from $246K to $399K.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.